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Abstract
Background: In recent years, research has consistently proven the occurrence of genetic overlap across autoimmune
diseases, which supports the existence of common pathogenic mechanisms in autoimmunity. The objective of this
study was to further investigate this shared genetic component.
Methods: For this purpose, we performed a cross-disease meta-analysis of Immunochip data from 37,159 patients
diagnosed with a seropositive autoimmune disease (11,489 celiac disease (CeD), 15,523 rheumatoid arthritis (RA), 3477
systemic sclerosis (SSc), and 6670 type 1 diabetes (T1D)) and 22,308 healthy controls of European origin using the R
package ASSET.
Results: We identified 38 risk variants shared by at least two of the conditions analyzed, five of which represent new
pleiotropic loci in autoimmunity. We also identified six novel genome-wide associations for the diseases studied. Cell-
specific functional annotations and biological pathway enrichment analyses suggested that pleiotropic variants may
act by deregulating gene expression in different subsets of T cells, especially Th17 and regulatory T cells. Finally, drug
repositioning analysis evidenced several drugs that could represent promising candidates for CeD, RA, SSc, and T1D
treatment.
Conclusions: In this study, we have been able to advance in the knowledge of the genetic overlap existing
in autoimmunity, thus shedding light on common molecular mechanisms of disease and suggesting novel
drug targets that could be explored for the treatment of the autoimmune diseases studied.
Keywords: Celiac disease, Rheumatoid arthritis, Systemic sclerosis, Type 1 diabetes, Cross-disease meta-analysis,
Immunochip, Autoimmune disease, functional enrichment analysis
Background
Autoimmune diseases present a complex etiology result-
ing from the interaction between both genetics and en-
vironmental factors. Although these conditions differ in
their clinical manifestations, the existence of familial
clustering across them as well as the co-occurrence of
multiple immune-mediated disorders in the same
individual points to the existence of a common genetic
background in autoimmunity [1].
As a matter of fact, genomic studies have revealed that
many genetic loci are associated with multiple immune-me-
diated phenotypes, thus suggesting that autoimmune disor-
ders are likely to share molecular mechanisms of disease
pathogenesis [2, 3]. In the last years, several approaches have
been conducted to comprehensively explore this genetic
overlap. In this regard, combined analysis of GWAS (geno-
me-wide association study) or Immunochip data across mul-
tiple diseases simultaneously has emerged as a powerful
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strategy to identify novel pleiotropic risk loci as well as com-
mon pathogenic mechanisms in autoimmunity [4, 5]. Re-
cently, a cross-phenotype study combining Immunochip
data from five seronegative autoimmune diseases, including
ankylosing spondylitis, Crohn’s disease (CD), psoriasis, pri-
mary sclerosing cholangitis and ulcerative colitis, identified
numerous multidisease signals, some of which represented
new pleiotropic risk loci in autoimmunity [4].
Considering the above, we decided to perform a simi-
lar approach by exploring genetic overlap across four
seropositive autoimmune diseases. Specifically, Immuno-
chip data from 37,159 patients with celiac disease (CeD),
rheumatoid arthritis (RA), systemic sclerosis (SSc) and
type 1 diabetes (T1D) and 22,308 unaffected individuals
were combined in a cross-disease meta-analysis. The
aims of this study were (i) to identify new susceptibility
loci shared by subsets of these four immune-related con-
ditions, (ii) to identify new associations for individual
diseases, and (iii) to shed light into the molecular mech-
anisms shared among these four disorders by integrating
genotype and functional annotation data.
Methods
Study population
All samples were genotyped using Immunochip (Illu-
mina, Inc., CA), a custom array designed for dense geno-
typing of 186 established genome-wide significant loci.
The cohorts included in the present study are described
in Additional file 1: Table S1. The CeD cohort, com-
posed of 11,489 cases from Italy, the Netherlands, Spain,
and the UK, and the RA cohort, which included 13,819
cases from Spain, the Netherlands, Sweden, the UK, and
the USA, came from a previous published meta-
Immunochip [6]. In addition, 1788 RA samples from
Spain (which did not overlap with the Spanish RA cases
included in the Immunochip mentioned) were also ana-
lyzed. These patients were recruited in three different
Spanish hospitals (Hospital Marqués de Valdecilla, San-
tander, Hospital Clínico San Carlos, Madrid and Hos-
pital La Princesa, Madrid) and were diagnosed with RA
according to the 1987 classification criteria of the
American College of Rheumatology [7]. The T1D set
consisted of 6670 cases from the UK and has been de-
scribed in a previous Immunochip study [8]. Finally, the
SSc cohort, which consisted of 3597 cases from Spain,
the USA, the UK, Italy, and the Netherlands, was also
described in a previous Immunochip study [9].
Additionally, 22,365 ethnically matched control indi-
viduals were analyzed. As indicated in Additional file 1:
Table S1, some of the control sets, specifically those
from Italy, the Netherlands, Spain, and the UK, over-
lapped among different diseases, which was taken into
account for the subsequent cross-disease meta-analysis.
Quality control and imputation
Before imputation, data quality control was performed
separately for each cohort using PLINK 1.9 [10].
Single-nucleotide polymorphisms (SNPs) with low call
rates (< 98%), low minor allele frequency (MAF < 0.01)
and those that were not in Hardy-Weinberg equilibrium
(HWE; p < 0.001) were excluded. Individuals with suc-
cessful call rates lower than 95% were also removed.
Additionally, an individual of each pair of duplicates and
first-degree relatives identified via the Genome function
in PLINK 1.9 (PI-HAT > 0.4) was randomly discarded.
IMPUTE V.2 was used to perform SNP genotype im-
putation [11] using the 1000 Genomes Phase III as refer-
ence panel [12]. To maximize the quality of imputed
SNPs, a probability threshold for merging genotypes of
0.9 was established. Imputation accuracy, measured as
the correlation between imputed and true genotypes,
considering the best-guess imputed genotypes (> 0.9
probability) was higher than 99% for all the analyzed co-
horts. Imputed data were subsequently subjected to
stringent quality filters in PLINK 1.9. Again, we filtered
out SNPs with low call rates (< 98%) and low MAF (<
0.01) and those that deviated from HWE (p < 0.001).
Moreover, after merging case/control sets, singleton
SNPs and those showing strong evidence of discordance
in genotype distribution between cases and controls due
to possible miscalling were removed using an in-house
Perl script.
To account for spurious associations resulting from
ancestry differences among individuals, principal compo-
nent (PC) analyses were performed in PLINK 1.9 and
the gcta64 and R-base under GNU Public license V.2.
We calculated the 10 first PCs using the markers in-
formative of ancestry included in the Immunochip. Sub-
jects showing more than four SDs from cluster centroids
were excluded as outliers.
After applying quality control filters and genome
imputation, we analyzed 252,970 polymorphisms in
37,159 autoimmune-disease patients (11,489 CeD,
15,523 RA, 3477 SSc, and 6670 T1D) and 22,308
healthy controls.
Statistical analysis
Disease-specific analysis
First, we performed association analyses within each spe-
cific disease. For this, each case/control set was analyzed
by logistic regression on the best-guess genotypes (> 0.9
probability) including the first ten PCs as covariates in
PLINK 1.9. Then, for CeD, RA, and SSc, for which sev-
eral independent case/control sets were available, we
combined the different cohorts (Additional file 1: Table
S1) using inverse variance weighted meta-analysis in
METASOFT [13]. The human leukocyte antigen (HLA)
region (Chr6: 20–40MB) and sex chromosomes were
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excluded. Genomic inflation factor lambda (λ) was cal-
culated using 3120 SNPs included in the Immunochip
that map to non-immune regions. In addition, to ac-
count for inflation due to sample size [14], we calculated
λ1000, the inflation factor for an equivalent study of 1000
cases and 1000 controls. Quantile–quantile plots for the
p values of each individual disease are shown in Add-
itional file 2: Figure S1a-d.
Cross-disease meta-analysis
Subsequently, summary level data obtained from the as-
sociation studies of each specific disease were used to
identify pleiotropic SNPs (shared by at least two of the
autoimmune diseases analyzed). For this purpose, we
performed a subset-based meta-analysis applying the “h
traits” function as implemented in ASSET [15]. ASSET
is an R statistical software package specifically designed
for detecting association signals across multiple studies.
This method does not only return a p value, but it also
shows the best subset containing the studies contribut-
ing to the overall association signal. Moreover, this
method allows for accounting for shared subjects across
distinct studies using case/control overlap matrices.
Since some of the control sets included in the
disease-specific association analyses were shared among
different diseases, we used correlation matrices to adjust
for the overlapping of control individuals. Quantile–
quantile plot for the p values from the cross-disease
meta-analysis is shown in Additional file 2: Figure S1e.
After subset-based meta-analysis, SNPs for which
two-tailed p values were lower than 5 × 10− 8 were consid-
ered statistically significant. Genetic variants showing ef-
fects in opposite directions across diseases were considered
as significant when p values for both positively and nega-
tively associated subsets reached at least nominal signifi-
cance (p < 0.05). For regions where several SNPs reached
genome-wide significance, we considered as lead variants
those for which the best subset included a higher number
of diseases. Subsequently, in order to identify independent
signals, we linkage disequilibrium (LD)-clumped the results
of the subset-based meta-analysis using PLINK to select
polymorphisms with r2 < 0.05 within 500-kb windows and
at genome-wide significant level.
Confirmation of pleiotropic effects identified by ASSET
To assess the reliability of our findings, ASSET results
were compared with those obtained using an alternative
approach, the compare and contrast meta-analysis
(CCMA) [16]. For pleiotropic variants identified using
ASSET, we calculated z-scores for each disease-specific
association analysis as well as for all the possible combi-
nations of diseases, assuming an agonistic or an antag-
onistic effect of the variants. For each locus, the subset
showing the largest z-score was considered as the best
model. p values for the maximum z-scores were derived
using an empirical null distribution by simulating
300,000,000 realizations of four normally distributed
random variables (p value < 1.00E−08 for z-score ≥ 6.45)
(Additional file 2: Figure S2) [16].
Identification of novel genome-wide associations
We investigated whether pleiotropic SNPs were associ-
ated at genome-wide significance level with any of the
diseases included in the best subset. To such purpose,
we checked the results for these variants in each
disease-specific association analysis. Additionally, in the
case of SNPs associated with a specific disease, the stat-
istical power of the subset-based analysis is lower than
that of standard meta-analysis, as a result of a
multiple-testing penalty associated with comprehensive
subset searches. Consequently, the SNPs showing p
values < 5 × 10− 6 in the subset-based meta-analysis were
also tested for association in each specific disease.
Gene prioritization
To identify the most likely causal genes at associated loci,
independent signals were annotated using several data-
bases. First, all associated genetic variants were annotated
using the variant effect predictor (VEP) [17]. Then, we
used Immunobase [18] and the GWAS catalog [19] to ex-
plore whether the lead SNPs—or variants in LD with them
(r2 ≥ 0.2) according to the European population of the
1000 Genomes Project—had been previously associated
with immune-mediated diseases at genome-wide signifi-
cance level. For SNPs for which clear candidate genes have
already been reported, we considered these as the most
probable genes. On the other hand, in the case of SNPs
for which clear candidate genes have not been reported,
we took into account VEP annotations, as follows: for
SNPs annotated as coding, we reported the gene where
each particular variant mapped; for SNPs annotated as in-
tronic, upstream, downstream, or intergenic, we priori-
tized genes by using DEPICT (Data-driven Expression-
Prioritized Integration for Complex Traits). DEPICT is an
integrative tool that employs predicted gene functions to
systematically prioritize the most likely causal genes at as-
sociated loci [20].
Functional annotation and enrichment analysis
Functional annotation of lead polymorphisms and their
correlated variants (r2 ≥ 0.8) was performed using pub-
licly available functional and biological databases. On
the one hand, the possible functional impact of
non-synonymous SNPs was evaluated using SIFT [21].
On the other hand, Haploreg v4.1 [22] was used to ex-
plore whether SNPs overlapped with conserved positions
(Genomic Evolutionary Rate Profiling: GERP), tissue-
specific chromatin state methylation marks (promoter
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and enhancer marks) based on the core-HMM 15 state
model, tissue-specific DNase I hypersensitive sites
(DHSs), tissue-specific transcription factor binding sites
(TFBSs), and/or published expression quantitative trait
locus (eQTL) signals in immune cell lines, cell types
relevant for each specific disorder, and/or whole blood.
Sources of Haploreg v4.1 include public datasets from
the Roadmap Epigenomics project, the Encyclopedia of
DNA Elements (ENCODE) Consortium and more than
10 eQTL studies, including the Genotype-Tissue Expres-
sion (GTEx) project.
Additionally, we used the GenomeRunner web server
[23] to determine whether the set of pleiotropic SNPs sig-
nificantly co-localized with regulatory genome annotation
data in specific cell types from the ENCODE and Road-
map Epigenomics projects. Briefly, GenomeRunner calcu-
lates enrichment p values using Chi-squared test by
evaluating whether a set of SNPs of interest co-localizes
with regulatory datasets more often that could happen by
chance. Specifically, we tested for overrepresentation of
161 TFBSs from the ENCODE project and histone modifi-
cations (acetylation of histone H3 at lysine 27 (H3K27ac),
mono-methylation of histone H3 at lysine 4 (H3K4me1),
and tri-methylation of histone H3 at lysine 4 (H3K4me3))
and DHSs in 127 cell types from the Roadmap Epige-
nomics project. Regulatory enrichment p values were cor-
rected for multiple testing using the Benjamini–Hochberg
false discovery rate (FDR) procedure.
Identification of common molecular mechanisms
Next, we performed protein-protein interaction (PPI)
and pathway analysis to evaluate the existence of bio-
logical processes enriched among the set of pleiotropic
loci. PPI analysis was conducted using STRING 10.5
[24], a database of direct (physical) and indirect (func-
tional) interactions derived from five main sources:
genomic context prediction, high-throughput lab experi-
ments, co-expression, text mining, and previous know-
ledge in databases. In STRING, each PPI is annotated
with a score, ranging from 0 to 1, which indicates the
confidence of the interaction. We also used the list of
common genes to perform KEGG pathway analysis using
WebGestalt (WEB-based GEne SeT AnaLysis Toolkit)
[25] with the human genome as reference set, the Benja-
mini Hochberg adjustment for multiple testing, and a
minimum number of two genes per category.
Drug repurposing analysis
Finally, we investigated whether drugs currently used for
other indications could be used for the treatment of RA,
CeD, T1D, and/or SSc by using DrugBank (version 5.0.9,
released 2017-10-02). DrugBank is a database containing
10,507 drug entries as well as 4772 non-redundant pro-
tein sequences linked to these drugs [26]. First, we
identified genes in direct PPI with the pleiotropic genes
by using STRING 10.5 [24], with a minimum required
interaction score of 0.700 (high confidence) and exclud-
ing “text mining” as a source of interaction prediction.
Subsequently, we searched DrugBank to identify pleio-
tropic genes, and genes in direct PPI with them, which
are targets for approved, clinical trial or experimental
pharmacologically active drugs.
Results
Cross-disease meta-analysis
After applying quality control filters and imputation, we
analyzed Immunochip data from 37,159 patients diag-
nosed with an autoimmune disease (11,489 CeD, 15,523
RA, 3477 SSc, and 6670 T1D) and 22,308 healthy con-
trols, all of them of European origin. We performed a
subset-based association analysis using ASSET [15] to
identify SNPs shared by at least two of the autoimmune
conditions analyzed as well as the best subset of diseases
contributing to the association signal. Summary statistics
from the subset-based meta-analysis are available in
Additional file 3. We observed 60 loci containing at least
one genetic variant at genome-wide significance (p value
≤5 × 10− 08) in the meta-analysis (Additional file 2: Figure
S3). After LD clumping, an independent association was
found for 69 genetic variants within those genomic re-
gions, 31 of which were associated with individual dis-
eases and 38 were shared by two or more phenotypes
(Additional file 1: Table S2).
The 38 identified common variants mapped on 34 dif-
ferent genomic regions (Table 1 and Additional file 1:
Table S2). According to the GWAS Catalog and Immu-
nobase [18, 19], five of these shared loci (PADI4 at
1p36.13, NAB1 at 2q32.3, COBL at 7p12.1, CCL21 at
9p13.3, and GATA3 at 10p14) have been associated with
a single autoimmune disease so far and thus they repre-
sent new pleiotropic loci in autoimmunity. We also ob-
served several independent signals within three known
shared risk loci, four of which (rs1217403 in PTPN22,
rs6749371 and rs7574865 in STAT4, and rs17753641 in
IL12A) are new signals for some of the diseases contrib-
uting to the association (Table 1 and Additional file 1:
Table S2). For example, we identified two independent
variants associated with RA and T1D in PTPN22:
rs2476601—a known risk variant for both conditions—
and rs1217403—which is not linked to the SNPs previ-
ously associated with RA and T1D (r2 = 0.03). Interest-
ingly, three independent multi-disease signals were
detected within the 2q32.3 region, two of them
(rs6749371 and rs7574865) located within STAT4 and
another one (rs10931468) located within the NAB1 gene
(Table 1 and Additional file 1: Table S2). Interestingly,
this last locus has not been previously associated with
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Table 1 Independent genetic variants reaching genome-wide level of significance in the subset-based meta-analysis and showing
pleiotropic effects across diseases
Region Position (bp) SNP Gene A1 P2sided Best subset
1p36.32 2,534,978 rs6664969 MMEL1 A 2.86E−10 CeD RA
1p36.13 17,655,407 rs1748041 PADI4 C 3.63E−08 RA SSc
1p13.2 114,377,568 rs2476601 PTPN22 A 6.36E−119 RA T1D
1p13.2 114,388,804 rs1217403 PTPN22 C 4.66E−11 RA* T1D*
1q24.3 172,674,776 rs10912267 FASLG A 3.90E−09 CeD T1D
2q11.2 100,764,004 rs13415465 AFF3 G 3.72E−12 CeD RA T1D
2q31.3 182,057,640 rs12619531 ITGA4 G 1.18E−18 CeD SSc
2q32.3 191,538,562 rs10931468 NAB1 A 1.56E−08 RA SSc
2q32.3 191,902,184 rs6749371 STAT4 T 3.84E−08 CeD SSc*
2q32.3 191,964,633 rs7574865 STAT4 T 3.16E−09 CeD* RA SSc T1D*
2q33.2 204,612,058 rs7426056 CD28 A 6.68E−12 CeD RA
2q33.2 204,738,919 rs3087243 CTLA4 A 5.08E−16 RA T1D
3p14.3 58,183,636 rs35677470 DNASE1L3 A 1.04E−11 RA SSc
3q25.33 159,647,674 rs17753641 IL12A G 1.64E−29 CeD SSc*
4p15.2 26,088,128 rs16878091 RBPJ A 2.53E−12 RA T1D
5q33.1 150,438,988 rs1422673 TNIP1 T 1.87E−09 CeD RA SSc
6q15 90,976,768 rs72928038 BACH2 A 9.34E−12 CeD RA T1D
6q23.3 138,003,822 rs11757201 TNFAIP3 C 1.27E−11 CeD RA T1D
6q23.3 138,243,739 rs58721818 TNFAIP3 T 5.26E−10 RA SSc
6q25.3 159,470,417 rs212407 TAGAP G 6.74E−14 CeD RA T1D
7p14.1 37,382,465 rs60600003 ELMO1 G 4.25E−13 CeD SSc
7p12.1 51,015,193 rs7780389 COBL T 2.25E−08 RA T1D
7q32.1 128,572,766 rs4731532 IRF5 A 1.25E−10 RA SSc
9p13.3 34,710,260 rs2812378 CCL21 G 1.04E−09 CeD RA
10p15.1 6,101,713 rs3118470 IL2RA C 5.92E−09 RA T1D
10p15.1 6,116,254 rs72776098 IL2RA A 7.10E−10 SSc T1D
10p15.1 6,390,450 rs947474 PRKCQ G 1.28E−08 CeD RA T1D
10p14 8,102,272 rs3802604 GATA3 G 4.67E−08 RA T1D
10q22.3 81,045,280 rs1250568 ZMIZ1 C 3.87E−15 CeD SSc T1D
11q23.3 118,726,843 rs10892299 DDX6 T 2.25E−13 CeD SSc T1D
12q13.2 56,470,625 rs11171739 IKZF4 C 1.87E−20 RA T1D
15q14 38,828,140 rs8043085 RASGRP1 T 1.53E−08 RA T1D
15q25.1 79,234,957 rs34593439 CTSH A 1.47E−14 CeD T1D
17q12 38,033,277 rs1054609 ORMDL3 C 3.70E−08 RA SSc T1D
18p11.21 12,777,573 rs2542148 PTPN2 C 5.11E−16 CeD T1D
19p13.2 10,427,721 rs74956615 TYK2 A 1.62E−17 RA SSc T1D
21q22.3 43,855,067 rs1893592 UBASH3A C 4.86E−12 CeD T1D
22q11.1 21,936,152 rs66534072 YDJC G 2.05E−08 CeD SSc
The selected lead SNP in each region is shown, together with the best subset obtained from the subset-based meta-analysis. Position (bp), base pair position in
hg19; SNP, single nucleotide polymorphism; Gene, annotated gene as described in methods; A1, alternative allele used in the logistic regression; P2sided, p value
from the two-sided subset-based meta-analysis; Best subset, phenotypes contributing to the association signal. Diseases included in the best subset and for which
identified associations have not been previously reported are shown in bold; novel signals within known risk loci are indicated by “*”
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any of the diseases contributing to the association signal,
RA, and SSc.
On the other hand, an opposite effect was observed
for ten of the shared genetic variants that mapped on
ITGA4, IL12A, TNIP1, TAGAP, COBL, IL2RA, ZMIZ1,
DDX6, IKZF4, and CTSH regions (Additional file 2: Fig-
ure S4 and Table S3). For example, the minor allele (G)
of the IL12A rs17753641 polymorphism, which has been
previously reported to confer risk to CeD, had a protect-
ive effect for SSc in our study. In addition, an opposite
effect was also observed for the TAGAP rs212407 vari-
ant, which appeared to confer risk to CeD and protec-
tion to RA and T1D, as previously described [6, 27].
In order to validate our findings, the pleiotropic role
of the shared variants identified by ASSET was evaluated
using the CCMA approach. As shown in Additional file 1:
Table S4, 34 of the 38 SNPs had a pleiotropic effect ac-
cording to CCMA (best model including at least two
diseases). It should be noted that the second best model
obtained with this method yielded z-scores very similar
to those of the best model. In this regard, when consid-
ering either of the two best models, all pleiotropic SNPs
identified by ASSET showed shared effects across dis-
eases in the CCMA (Additional file 1: Table S4). Fur-
thermore, we observed a high concordance rate between
the best subset of diseases identified by ASSET and the
best models (best or second best model) according to
CCMA. Specifically, best models completely matched
between both methods for 29 of the 38 SNPs (concord-
ance rate of 0.76). In addition, for the remaining 9 pleio-
tropic variants, best models partially overlapped between
ASSET and CCMA and, in all the cases except one, dis-
eases contributing to the association signal according to
ASSET were included in the best model of CCMA (Add-
itional file 1: Table S4). For instance, whereas ASSET
identified two diseases (CeD and SSc) contributing to
the association signal observed for rs60600003, the best
model obtained with CCMA included three diseases, the
two already forming part of the best subset of ASSET
(CeD, SSc) and RA. Considering those SNPs for which
the best model overlapped totally or partially between
both approaches, the concordance rate between ASSET
and CCMA was 0.87, considering the best model of
CCMA, and 1, considering the best or second best
model of CCMA. This analysis confirms the high reli-
ability of our cross-disease meta-analysis results,
strongly supporting the role of the 38 genetic variants as
pleiotropic risk factors in autoimmunity.
Identification of novel individual-disease associations
Of the 34 shared risk loci identified, 20 have already been
reported as risk factors for the diseases contributing to the
association, according to Immunobase and the GWAS
catalog [18, 19], whereas 14 of them (more than 40%)
represent potentially new loci for at least one of the dis-
eases included in the best subset (Table 1). Considering
this, we checked whether these pleotropic variants were
associated at genome-wide level of significance with any
of the diseases contributing to each specific signal. Two of
the common variants, rs10931468 (mapping on the NAB1
region, 2q32.3) and rs10892299 (mapping on the DDX6
region, 11q23.3), were associated with RA and SSc, re-
spectively (Fig. 1, Additional file 2: Figures S5a and S6a,
and Additional file 1: Table S2); hence they represent
novel genetic risk factors for these diseases. The
rs10931468 genetic variant is located within the NAB1
gene, near STAT4 (Table 1). However, this SNP is not
linked to the STAT4 variants previously associated with
the diseases under study (D’ < 0.13 and r2 < 0.012). In fact,
this SNP showed an independent effect in the RA
meta-analysis after conditioning on the most associated
variants within the region (Additional file 2: Figure S5b).
In addition, to avoid any loss of power, SNPs associ-
ated with a single disease and reaching p values lower
than 5 × 10− 6 in the subset-based meta-analysis were
checked for association in each specific disorder. Using
this strategy, we identified four novel single-disease
genome-wide associations, one for CeD (rs6806528 at
FRMD4B), two for SSc (rs4258254 at TNFSF4 and
rs17849502 at NCF2), and one for T1D (rs4238595 at
UMOD) (Fig. 1, Additional file 2: Figures S6-S8, and
Additional file 1: Table S5).
Functional annotation of associated variants
SNP annotation showed that only 5% of the pleiotropic
SNPs were coding, including two missense variants
(Additional file 1: Table S2), whereas five of the non-coding
SNPs (13%) were in tight LD (r2 ≥ 0.8) with coding variants
(three missense, one synonymous and one splice donor)
(Additional file 2: Table S6). Two of the non-synonymous
polymorphisms, rs35677470 within DNASE1L3 and
rs2289702 (a proxy for rs34593439) within CTSH, appeared
to have a deleterious effect according to SIFT
(Additional file 1: Table S2). Of the four new single-disease
signals, three were non-coding polymorphisms and one
was a missense variant (Additional file 1: Table S5).
Considering that most of the associated genetic vari-
ants did not show direct effects on protein function, we
identified all SNPs in high LD (r2 ≥ 0.8) with both pleio-
tropic and single-disease lead signals and evaluated their
possible functional implications. We checked for overlap
between the lead and proxy SNPs and functional annota-
tions from the Roadmap Epigenomics, ENCODE and
GTEx projects, including conserved positions, histone
modifications at promoters and enhancers, DHS, TFBS,
and eQTL. As shown in Fig. 2, all pleiotropic SNPs lie in
predicted regulatory regions in immune cell lines or
whole blood, whereas 76% overlap with more than three
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functional annotations. In addition, most of them appear
to act as eQTLs, thereby affecting gene expression levels
(Fig. 2 and Additional file 1: Table S7).
Similarly, all single-disease-associated variants also
overlapped with regulatory elements in whole blood, im-
mune cells, and/or cell types relevant for each specific
disorder (Fig. 2 and Additional file 1: Table S7).
Enrichment in tissue-specific regulatory elements and
biological pathways
Subsequently, to determine whether the set of 38 independ-
ent pleiotropic SNPs was enriched for regulatory elements
in specific cell types, we performed a hypergeometric test
using GenomeRunner [23]. Specifically, we checked for
overrepresentation of DHSs, histone modifications (H3K
27ac, H3K4me1, and H3K4me3), and TFBSs in human cell
lines and tissues from the ENCODE and Roadmap Epige-
nomics projects. Results of this analysis are shown in Fig. 3a
and Additional file 1: Table S8. Pleiotropic SNPs showed
overrepresentation of DHSs in different subsets of T cells,
with the strongest enrichment pointing to regulatory T
(Treg) cells, T helper memory and naive cells, and Th17
lymphocytes. Similarly, the H3k4me1, H3k27ac, and
H3k4me3 histone marks—which are especially informative
of most active enhancer and promoter regulatory regions—
were also overrepresented in these specific cell types (Fig. 3a
and Additional file 1: Table S8). In addition, shared genetic
variants were enriched for targets of 12 TFs, with BATF
(PBH = 6.40E−15), RelA (PBH = 6.11E−12), and IRF4 (PBH =
1.88E−08) showing the strongest overrepresentation
(Additional file 2: Table S9).
We further conducted PPI and KEGG pathway ana-
lysis to gain insight into the biological processes af-
fected for the set of common genes. By constructing a
network of direct and indirect interactions, we found a
main cluster enriched for proteins involved in Th1 and
Fig. 1 Novel genome-wide associated loci for celiac disease, rheumatoid arthritis, systemic sclerosis and type 1 diabetes. Pleiotropic SNPs reaching
genome-wide significance level and SNPs associated with a single disease and reaching p values lower than 5 × 10− 6 in the subset-based meta-analysis
were checked for genome-wide association in each of the diseases included in the best subset. Negative log10-tranformed p value (disease-specific p
values) (upper plot) and odds ratio (lower plot) for the new genome-wide signals are shown. The six loci are annotated with the candidate gene symbol.
Circles represent the analyzed diseases (red: celiac disease; yellow: rheumatoid arthritis; green: systemic sclerosis; blue: type 1 diabetes). The red line
represents genome-wide level of significance (p= 5 × 10− 8)
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Th2 cell differentiation (PBH = 6.21E−07), Jak-STAT sig-
naling pathway (PBH = 4.53E−03), T cell receptor signal-
ing pathway (PBH = 7.85E−03), and Th17 cell
differentiation (PBH = 7.85E−03) (Fig. 3b and Add-
itional file 2: Table S10).
Identification of potential drug targets
Finally, in order to identify potentially new leads for
therapies for CeD, RA, SSc, and T1D, we investigated
whether proteins encoded by pleiotropic genes—or any
gene in direct PPI with them—are targets for approved,
clinical trial, or experimental pharmacologically active
drugs. Using this approach, we found 26 potentially
repositionable drugs: 8 indicated for RA that would be
worth exploring for CeD, SSc, and/or T1D treatment
and 18 with other indications that could be promising
candidates for the treatment of at least two of the four
autoimmune diseases under study (Table 2). Interest-
ingly, 15 of the 19 drug targets identified among the set
of common genes are involved in the biological path-
ways overrepresented in the set of autoimmune disease
common genes (Fig. 3b).
Discussion
Through a large cross-disease meta-analysis of Immuno-
chip data from four seropositive autoimmune disorders,
CeD, RA, SSc, and T1D, we have been able to advance
in the knowledge of the genetic overlap existing in auto-
immunity. Specifically, our meta-analysis identified 38
genetic variants shared among subsets of the diseases
under study, five of which, including PADI4, NAB1,
COBL, CCL21, and GATA3, represent new shared gen-
etic risk loci. Moreover, ten of the 38 pleiotropic variants
showed opposite allelic effects across phenotypes con-
tributing to the association signal, thus indicating the
complexity of the molecular mechanisms by which SNPs
affect autoimmune diseases.
Fig. 2 Functional annotation of 38 pleiotropic polymorphisms (p< 5 ×
10–8 in the subset-based meta-analysis) and four single-disease
associated variants (p< 5 × 10–6 in the subset-based meta-analysis and p
< 5 × 10–8 in disease-specific meta-analyses). Haploreg v4.1 was used to
explore whether lead SNPs, and their proxies (r2≥ 0.8), overlapped with
different regulatory datasets from the Roadmap Epigenomics project, the
ENCODE Consortium and more than ten eQTL studies in immune cell
lines, cell types relevant for each specific disorder and/or whole blood.
Colors denote both lead and proxy SNPs overlapping with the different
regulatory elements analyzed: G (red): conserved positions (Genomic
Evolutionary Rate Profiling, GERP); P (orange): promoter histone marks; E
(yellow): enhancer histone marks; D (green): DNase I hypersensitive sites
(DHS); T (blue): transcription factor binding sites (TFBSs); eQ (purple):
expression quantitative trait loci (eQTL). Functional annotations
overlapping with proxy SNPs are marked with an asterisk. N proxy,
number of proxy SNPs for each lead variant. The different loci are
annotated with the candidate gene symbol
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Consistent with previous findings [28], functional anno-
tation of these pleiotropic polymorphisms suggested that
the majority of multi-disease signals affect disease risk by
altering gene regulation. Interestingly, tissue-specific en-
richment analysis for regulatory elements suggested a spe-
cific regulatory role of the pleiotropic variants in Th17
and Treg cells, thus pointing to a crucial contribution of
these cell types to the pathogenic mechanisms shared by
these disorders. In addition, enrichment for targets of sev-
eral TFs, mainly BATF, RelA, and IRF4, was also evident.
It should be noted that BATF and IRF4 are both required
for the differentiation of Th17 cells [29], whereas RelA is
crucial for Treg-induced tolerance [30]. According to this
data, pleiotropic variants could potentially regulate gene
expression by disrupting motifs recognized for TFs in
different subsets of T cells, mainly Th17 and Treg
Fig. 3 Functional regulatory elements and PPI enrichment analysis. a Heat map showing DNase 1 hypersensitive sites (DHSs) and histone marks
enrichment analysis of the set of pleiotropic variants. GenomeRunner web server was used to determine whether the set of pleiotropic SNPs
significantly co-localize with regulatory genome annotation data in 127 cell types from the Roadmap Epigenomics project. First column shows
cell types grouped and colored by tissue type (color-coded as indicated in the legend). Tissues relevant for the autoimmune diseases studied as
well as other tissues for which any of the analyzed functional annotations showed a significant enrichment p value (p < 0.05 after FDR correction)
are shown. The remaining four columns denote the analyzed functional annotations, DHSs, H3K27ac, H3K4me1, and H3K4me3. Results of the
enrichment analysis are represented in a scale-based color gradient depending on the p value. Blue indicates enrichment and white indicates no
statistical significance after FDR adjustment. b Interaction network formed for the set of common genes. Direct and indirect interactions among
genes shared by different disease subgroups were assessed using STRING. Plot shows results of the “molecular action” view such that each line
shape indicates the predicted mode of action (see legend). Genes involved in the biological pathways enriched among the set of pleiotropic loci
(Additional file 2: Table S10) are shown in color: red: Th1 and Th2 cell differentiation; green: Th17 cell differentiation; yellow: Jak-STAT signaling
pathway; blue: T cell receptor signaling pathway
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lymphocytes. Subsequently, results from pathway enrich-
ment analysis confirmed the relevant contribution of
pleiotropic variants and target genes in T cell-mediated
immunity. Moreover, drug repositioning analysis evi-
denced several candidate drugs with potential new clinical
use for the diseases under study. Notably, most of these
drugs were directed against proteins involved in the bio-
logical processes overrepresented among the set of com-
mon genes and, therefore, their potential clinical
application to the treatment of CeD, RA, SSc, and T1D
appeared to be of special interest. However, it should be
considered that both the functional effects of pleiotropic
variants as well as the disease-causal genes remain elusive
in most cases, thus representing a limitation for drug re-
positioning. In addition, ten of these shared genetic vari-
ants showed opposite effects across diseases and,
therefore, the complexity of molecular mechanisms by
which SNPs affect autoimmune diseases should be taken
Table 2 Common genes in autoimmunity identified as targets for drugs
Annotated gene Genes in direct
PPI
Targeted drugs Action Indication Potential new
clinical application
Indicated for CeD, RA, T1D, and/or SSc
CD28 CD80 Abatacept Antagonist RA CeD
IL12A/TYK2 IL6R Tocilizumab Antibody RA CeD, SSc, T1D
Sarilumab Antagonist,
antibody
RA
IL1R1 Anakinra Antagonist RA
PTPN2/STAT4 JAK1/JAK2/JAK3 Tofacitinib Inhibitor RA CeD, SSc, T1D
TNFAIP3 TNF Etanercept Antibody RA CeD, SSc, T1D
Adalimumab Antibody RA
Infliximab Inhibitor RA
Other indications
CD28 CD2 Alefacept Inhibitor Psoriasis CeD, RA
CD28/IL12A/IL2RA/STAT4/
TYK2
IFNG Olsalazine NA Inflammatory bowel disease CeD, RA, SSc, T1D
CCL21 C5 Eculizumab Antibody Paroxysmal nocturnal
haemoglobinuria
CeD, RA
CXCR4 Plerixafor Antagonist Cancer
CCL21/IL12A/TYK2 CCR5 Maraviroc Antagonist HIV CeD, RA, SSc, T1D
CTLA4 Ipilimumab NA Cancer RA, T1D
FASLG/IL12A/IL2RA/IRF5
/STAT4/TYK2
IL12B Ustekinumab Antibody Psoriasis and psoriatic arthritis CeD, RA, SSc, T1D
IL12A/IL2RA/TYK2 IL3RA Sargramostim Agonist Cancer CeD, RA, SSc, T1D
IL12A/IRF5/TYK2 IL1B Canakinumab Binder Systemic juvenile idiopathic
arthritis
CeD, RA, SSc, T1D
IL12A/TYK2 IFNGR1 Interferon gamma-
1b
Chronic granulomatous
disease
CeD, RA, SSc, T1D
IL2RA Aldesleukin Agonist, Modulator Cancer CeD, RA, SSc, T1D
Basiliximab Antibody Kidney transplant rejection
Daclizumab Antibody Multiple sclerosis
Denileukin diftitox Binder Cancer
IL2RA/IRF5/TYK2 IL6 Siltuximab Antagonist
antibody
Castleman’s disease CeD, RA, SSc, T1D
IL2RA/STAT4/TYK2 IL23A Guselkumab Blocker Psoriasis CeD, RA, SSc, T1D
ITGA4 Natalizumab Antibody Multiple sclerosis CeD, SSc
Vedolizumab Antibody Crohn disease and ulcerative
colitis
Target genes for both drugs used for the treatment of the studied autoimmune diseases as well as drugs used for other indications are shown in the Table. NA,
not available. Last column indicates those diseases that could potentially benefit from drug repositioning, since they are contributing (included in the best subset)
to the association signal/s observed within each locus
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into account when prioritizing drugs based on reposi-
tioning studies.
Furthermore, we also reported six new genome-wide as-
sociations for the diseases under study. We identified two
new susceptibility loci for RA and SSc among the pleio-
tropic signals. The dense genotyping of immune-related
loci provided by the Immunochip platform allowed identi-
fying NAB1 as a new susceptibility locus for RA within the
2q22.3 region, which also contains the pan-autoimmune
susceptibility gene STAT4. In addition, interrogation of
publicly available eQTL data sets showed that the associ-
ated NAB1 variant, rs10931468, acts as an eQTL affecting
NAB1 expression in lymphoblastoid cell lines. NAB1 en-
codes the NGFI-A binding protein 1, which has been
shown to form a complex with Egr3 involved in the silen-
cing of interferon gamma receptor 1 (ifngr1). Specifically,
Nab1 was required for deacetylation of the ifngr1 pro-
moter and downregulation of cell surface receptor [31].
On the other hand, an intergenic variant located near
DDX6 was also identified as a new genetic risk locus for
SSc. This gene encodes a member of the DEAD box pro-
tein family recently identified as a suppressor of
interferon-stimulated genes [32].
Additionally, some of the single-disease genome-wide
associations identified in the present study had not been
previously reported. The FRMD4B locus was found to be
associated with CeD. Although genetic variants within the
FRMD4B region have been previously involved in disease
susceptibility [33, 34], our study is the first one reporting
an association between CeD and this locus at the
genome-wide significance level. FRMD4B, encoding a
scaffolding protein (FERM domain containing 4B protein),
has not been described before in relation to any auto-
immune disorder, representing a CeD-specific risk locus.
Regarding SSc, two new genetic risk loci were identi-
fied. According to the subset-based meta-analysis results,
SSc was the only phenotype contributing to the associ-
ation signal detected within the 1q25.1 region; however,
this locus is also a known susceptibility factor for RA
[35]. Indeed, several SNPs within this region showed
pleiotropic effects in RA and SSc in the cross-disease
meta-analysis, but they did not reach genome-wide sig-
nificance (top RA-SSc common signal: p value = 5.86E
−06). A relevant gene for the immune response, TNFSF4,
is located within the 1q25.1 region; nevertheless, func-
tional annotation revealed that the rs10798269 SNP (a
proxy for the top associated variant) acted as a
trans-eQTL influencing the expression level of the PAG1
gene (p value = 4.20E−06). Strikingly, PAG1, residing on
chromosome region 8q21.13, encodes a transmembrane
adaptor protein that binds to the tyrosine kinase csk par-
ticipating in the negative control of the signaling medi-
ated by the T cell receptor (TCR) [36]. It should be
noted that CSK is an established risk locus for SSc [37].
A second novel genome-wide association for SSc was
identified within the 1q25.3 region. The strongest signal
belonged to a missense variant (rs17849502), also associ-
ated with systemic lupus erythematosus [38], which
leads to the substitution of histidine-389 with glutamine
(H389Q) in the PB1 domain of the neutrophil cytosolic
factor 2 (NCF2) protein. NCF2 is part of the
multi-protein NADPH oxidase complex found in neu-
trophils. Interestingly, it has been shown that the 389Q
mutation has a functional implication, causing a twofold
decrease in reactive oxygen species production [38].
Finally, a genetic variant (rs4238595) located down-
stream of the UMOD gene, encoding uromodulin, was
identified as a new genetic risk factor for T1D. Interest-
ingly, a SNP linked to this variant showed nominal associ-
ation in a previous GWAS performed in this disorder
[39]. This locus has also been implicated in diabetic kidney
disease [40]. Nevertheless, no association with any other
immune-related condition has been described so far and,
therefore, this locus represents a T1D-specific association.
In addition, functional annotation of the lead variant and
their proxies showed an overlap with enhancer histone
marks and DHSs specifically in pancreas, which supports
its potential role in the T1D pathogenesis.
Conclusions
In summary, by conducting a subset-based meta-analysis
of Immunochip data from four seropositive autoimmune
diseases, we have increased the number of pleiotropic
risk loci in autoimmunity, identified new genome-wide
associations for CeD, SSc, RA, and T1D and shed light
on common biological pathways and potential functional
implications of shared variants. Knowledge of key shared
molecular pathways in autoimmune diseases may help
identify putative common therapeutic mechanisms. In
this regard, we identified several drugs used for other in-
dications that could be repurposed for the treatment of
the autoimmune diseases under study. Thus, a new clas-
sification of patients based on molecular profiles, rather
than clinical manifestations, will make it possible for in-
dividuals with a certain autoimmune disorder to benefit
from therapeutic options currently used to treat another
disease with which they share etiological similarities.
Due to the design of the Immunochip, all shared path-
ways identified in our study were related to immune
regulation. Hopefully, future cross-disease studies using
GWAS data will allow identification of non-immune loci
and pathways shared in autoimmunity.
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Additional file 1: Table S1. Case/control datasets included in the study.
Table S2. Loci reaching genome-wide level of significance in the subset-
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type 1 diabetes (p value < 5 × 10–6 in the subset based meta-analysis and
p value < 5 × 10–8 in each disease-specific meta-analysis). Table S7. Poten-
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ated variants), and their proxies (r2≥ 0.8) as expression quantitative trait loci
(eQTLs) in whole blood, immune cell lines or tissues relevant for the diseases
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Additional file 2: Table S3. Results of the subset-based meta-analysis
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1000 Genomes Project. Table S9. Transcription factor binding sites
(TFBSs) potentially disrupted by the set of pleiotropic variants. Table S10.
Biological pathways significantly enriched among the set of common
genes. Figure S1. Quantile–quantile plots for the p values of each indi-
vidual disease, celiac disease (a), rheumatoid arthritis (b), systemic scler-
osis (c), and type 1 diabetes (d), and the cross disease meta-analysis (e).
Figure S2. Empirical −log10(P)-distribution of the Zmax statistic obtained
by simulating 300 × 106 replicates of four normally distributed random
variables. Figure S3. Manhattan plot of the subset-based meta-analysis of
Immunochip data from celiac disease (CeD), systemic sclerosis (SSc),
rheumatoid arthritis (RA) and type 1 diabetes (T1D). Figure S4. Disease-
specific odds ratio for the pleiotropic variants showing opposite allelic ef-
fects across autoimmune diseases. Figure S5. Regional association plots
of the novel genome-wide associated locus for rheumatoid arthritis (RA),
2q32.3. Figure S6. Regional association plots of the novel genome-wide
associated loci for systemic sclerosis (SSc), 11q23.3 (a), 1q25.1 (b), and
1q25.3 (c). Figure S7. Regional association plot of the novel genome-
wide associated locus for celiac disease (CeD), 3p14.1. Figure S8. Re-
gional association plot of the novel genome-wide associated locus for
type 1 diabetes (T1D), 16p12.3. Members of the Coeliac Disease Immuno-
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